Grifols, S.A. GRFS
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -13.37%
- 1 year
- -11.57%
- Open
- 8.10
- Prev close
- 8.04
- Mkt cap
- 5.51B
- Vol
- 803.38K
- Avg vol
- 530.76K
- EPS
- 0.77
- P/E
- 10.52
- Div yield
- 1.32%
More statistics
- Low
- 8.05
- High
- 8.25
- Forward P/E
- 6.08
- Beta
- 1.20
- Short ratio
- 11.06
- Inst. own
- 57.27%
- Dividend
- 0.11
- Ex-div date
- Jul 1, 2026
- Earnings
- Nov 2, 2026
- 50-d avg
- 7.59
- 200-d avg
- 8.00
- 1y target
- 10.37
3M chart
Events in this range
- Oct 26, 2026Rating: JP Morgan · Neutral → Neutral
Signals (8)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 26, 2026 | 5 days ago |
| SMA: Bearish | Oct 20, 2026 | 1 week ago |
| SMA: Bullish | Oct 16, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 15, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 2, 2026 | 4 weeks ago |
| SMA: Bearish | Sep 10, 2026 | 1 month ago |
| SMA: Bearish | Aug 27, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 13, 2026 | 2 months ago |
Key statistics
- Market cap
- 5.51B
- Enterprise value
- 22.20B
- Trailing P/E
- 10.52
- Forward P/E
- 6.08
- PEG ratio
- 0.19
- Price / sales
- 0.74
- Price / book
- 1.77
- EPS (TTM)
- 0.77
- Beta
- 1.20
- Dividend yield
- 1.32%
- Payout ratio
- 37.97%
- Profit margin
- 6.09%
- Revenue (TTM)
- 7.42B
- Revenue growth
- -0.90%
- Free cash flow
- 572.92M
- Total cash
- 537.00M
- Total debt
- 9.36B
- Return on equity
- 6.93%
- Shares outstanding
- 258.22M
- Short % of float
- 0.00%
- 50-day average
- 7.59
- 200-day average
- 8.00
Analyst view
Consensus: buy
- Target (low)
- 9.00
- Target (mean)
- 10.37
- Target (high)
- 11.73
- Strong buy0
- Buy1
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 2, 2026
Expected Nov 2, 2026. Consensus EPS estimate 0.30396.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 2, 2026 | Sep 30, 2026 | 0.3202 | — | — | — |
| Jul 28, 2026 | Jun 30, 2026 | 0.27 | 0.2512 | -0.02 | -6.96% |
| May 7, 2026 | Mar 31, 2026 | 0.1613 | 0.1731 | +0.01 | +7.32% |
| Feb 26, 2026 | Dec 31, 2025 | 0.29 | 0.2891 | 0.00 | -0.31% |
| Nov 4, 2025 | Sep 30, 2025 | 0.2417 | 0.2108 | -0.03 | -12.78% |
| Jul 29, 2025 | Jun 30, 2025 | 0.23 | 0.19 | -0.04 | -17.39% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 26, 2026 | JP Morgan | main | Neutral | Neutral |
| Dec 8, 2025 | JP Morgan | main | Neutral | Neutral |
| Jun 17, 2025 | JP Morgan | main | Neutral | Neutral |
| Mar 12, 2024 | Deutsche Bank | down | Hold | Sell |
| Dec 5, 2023 | JP Morgan | main | Neutral | Neutral |
| Nov 5, 2021 | Deutsche Bank | down | Buy | Hold |
About Grifols, S.A.
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- Spain
- Website
- grifols.com
News
- Grifols Doses First Participants In Two Separate Phase 3 Studies To Expand U.S. Labels For Its GAMUNEX-C, XEMBIFY Subcutaneous Immunoglobulin
- Grifols Q1 Revenue €1.7 Billion Down From €1.786 Billion YoY
- Applied Digital, Simply Good Foods And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
- 'Grifols' Canadian License Restricted After Plasma Donor Deaths' - Bloomberg
- Grifols' Chronos-PD Study Demonstrates That Biological Changes In Individuals With Parkinson's Disease Occur More Than A Decade Before Clinical Diagnosis, With Potential Future Implications For Early Detection And Intervention
- Grifols Expects Reaching Free Cash Flow Pre-M&A Pre-Dividends Of €500M-575M; 2027 Milestones Unchanged; 2026 Adjusted EBITDA Margin Of Over 25%
- CORRECTION: JP Morgan Maintains Neutral on Grifols, Maintains $10 Price Target (Price Target Updated - Rating Originally Published on 8th Dec)
- JP Morgan Maintains Neutral on Grifols, Lowers Price Target to $10
- Verona Pharma, Rhythm Pharmaceuticals, AES And Other Big Stocks Moving Higher On Wednesday
- JP Morgan Maintains Neutral on Grifols, Raises Price Target to $10.3
Your note
Sign in to keep a note on GRFS — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Brandes Investment Partners L.P. | 14.47% | 37,816,285 | 306.31M | Jun 29, 2026 |
| Capital World Investors | 8.76% | 22,911,656 | 185.58M | Jun 29, 2026 |
| Permian Investment Partners, Lp | 7.55% | 19,740,679 | 159.90M | Jun 29, 2026 |
| Black Creek Investment Management Inc. | 2.94% | 7,682,055 | 62.22M | Jun 29, 2026 |
| Bank of America Corporation | 2.51% | 6,550,337 | 53.06M | Jun 29, 2026 |
| Millennium Management Llc | 1.67% | 4,369,934 | 35.40M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| NEW PERSPECTIVE FUND | 5.37% | 14,039,027 | 113.72M | Sep 29, 2026 |
| Intl Growth & Income Fd.-Intl Growth and Income Fd. | 1.98% | 5,180,416 | 41.96M | Sep 29, 2026 |
| Brandes Investment Trust-BRANDES INTERNATIONAL SMALL CAP EQUITY FUND | 1.84% | 4,803,459 | 38.91M | Jun 29, 2026 |
| iShares Trust-iShares Biotechnology ETF | 0.69% | 1,812,126 | 14.68M | Sep 29, 2026 |
| Brandes Investment Trust-BRANDES SMALL CAP VALUE FUND | 0.63% | 1,647,438 | 13.34M | Jun 29, 2026 |
| 2023 ETF Series Trust-Brandes International ETF | 0.34% | 893,153 | 7.23M | Jun 29, 2026 |